Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1501725
This article is part of the Research Topic The Pharmacological Effects and Mechanisms of Drugs Against Human Diseases by Modulating Redox Homeostasis - Volume II View all 4 articles

Gallic acid protects intervertebral disc cells from ferroptosis and alleviates intervertebral disc degeneration by regulating key factors of oxidative stress

Provisionally accepted
Zaishi Zhu Zaishi Zhu 1Zeling Huang Zeling Huang 1Chaofeng Zhang Chaofeng Zhang 1*Bo Xu Bo Xu 1*Hua Chen Hua Chen 1*Shuai Pei Shuai Pei 1*Baofei Zhang Baofei Zhang 1Lishi Jie Lishi Jie 2Xiaoqing Shi Xiaoqing Shi 1Yu'ji'ang Liu Yu'ji'ang Liu 1*Yuwei LI Yuwei LI 1*Xiaofeng Shen Xiaofeng Shen 1*
  • 1 Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, Jiangsu Province, China
  • 2 Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu Province, China

The final, formatted version of the article will be published soon.

    Intervertebral disc degeneration (IDD) is a chronic degenerative disease and one of the main causes of low back pain (LBP). Currently, there is no effective treatment. Ferroptosis is a cell-regulated process that depends on iron deposition and lipid peroxidation. Inhibiting ferroptosis in nucleus pulposus cells is considered a potential strategy for the treatment of IDD. Gallic acid (GA) is naturally present in a variety of plants and has anti-inflammatory, antioxidant and analgesic effects. It has been shown to alleviate ferroptosis. However, the role of GA in IDD ferroptosis remains unclear. This study explored the pathological mechanism of GA in IDD in relation to ferroptosis: (1) to identify ferroptosis-related targets for GA treatment of IDD using network pharmacology and molecular docking technology, (2) to evaluate the therapeutic effect of GA in an IDD rat model and changes in ferroptosis-related targets, (3) to investigate the changes of oxidative stress and lipid peroxidation products in NP cells after GA intervention, and (4) to study the changes of ferroptosis-related proteins and iron ions in cells and mitochondria after GA intervention. Experimental results confirmed that GA can treat IDD by reducing the degradation of extracellular matrix (ECM) and pathological changes in IDD. GA can also mitigate ferroptosis by reducing oxidative stress and lipid peroxidation in rat nucleus pulposus (NP) cells. The alleviation of disc degeneration ferroptosis by GA may be closely associated with the key ferroptosis proteins P53 and NRF2.

    Keywords: Ferroptosis1, intervertebral disc degeneration2, Oxidative Stress3, nucleus pulposus4, gallic acid5

    Received: 25 Sep 2024; Accepted: 17 Jan 2025.

    Copyright: © 2025 Zhu, Huang, Zhang, Xu, Chen, Pei, Zhang, Jie, Shi, Liu, LI and Shen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Chaofeng Zhang, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, 210023, Jiangsu Province, China
    Bo Xu, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, 210023, Jiangsu Province, China
    Hua Chen, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, 210023, Jiangsu Province, China
    Shuai Pei, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, 210023, Jiangsu Province, China
    Yu'ji'ang Liu, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, 210023, Jiangsu Province, China
    Yuwei LI, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, 210023, Jiangsu Province, China
    Xiaofeng Shen, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, 210023, Jiangsu Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.